LAURUSLABS1,942.50

Laurus Labs Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABGLANDMANKINDBIOCONALKEMLUPINFORTISGLENMARKMcap ₹1.05L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)278.06291.05305.94305.94
Receivable Days (DSO)120.41131.91115.46115.46
Payable Days (DPO)158.40144.06163.55127.65
Cash Conversion Cycle (days)240.07278.90257.85293.75
Working Capital Turnover6.987.015.717.40
Asset Turnover0.600.590.650.65
Cash Conversion (CFO/Net Income)4.101.681.821.82
CFO/EBITDA0.860.570.910.91
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.